Practice

Dr Marcus H. Snow: The US Launch of Renflexis

August 22nd 2017

By Marcus H. Snow, MD

Marcus H. Snow, MD, Assistant Professor Rheumatology, University of Nebraska, discusses the recent launch of a new biosimilar infliximab, Renflexis, in the United States.

Real-World Evidence Shows Biosimilar Filgrastim Safe, Effective Against Febrile Neutropenia

August 21st 2017

By Kelly Davio

Article

Febrile neutropenia (FN) is among the most common complications of chemotherapy, and a recent post-marketing, multi-center, real-world, non-interventional, epidemiological study sought to examine the use, safety, and efficacy of biosimilar filgrastim in the primary and secondary prevention of FN.

CVS Health Survey Finds Patients Ready for Cost-Saving Biosimilars

August 19th 2017

By The Center for Biosimilars Staff

Article

Pharmacy Benefit Manager CVS Health, which has over 90 million members, has released the results of a survey it conducted of approximately 2000 people in the United States concerning patient perceptions of generic and biosimilar medications.

LA-EP2006 as Effective, Safe as Reference Pegfilgrastim in Asian Patients With Breast Cancer

August 18th 2017

By Jackie Syrop

Article

Recombinant human granulocyte colony-stimulating factor (G-CSF), filgrastim, and its long-acting pegylated form, pegfilgrastim, are widely used to reduce the risk of chemotherapy-induced neutropenia, but to date, no pegfilgrastim biosimilar has been approved in highly regulated markets such as Europe, Japan, and the United States.

Bevacizumab Biosimilars Could Affect the Value of Systemic Therapy in Gynecologic Cancers

August 17th 2017

By Jackie Syrop

Article

Treatment guidelines for ovarian and cervical cancer recommend the use of the angiogenesis inhibitor bevacizumab (Avastin), but patient access to this medication and other angiogenesis inhibitors is limited.

Price Deals for Reference Products Pose a Threat to Biosimilars

August 16th 2017

By The Center for Biosimilars Staff

Article

While US healthcare providers are growing more willing to adopt lower-cost biosimilar drugs as way to address the rising costs of biologic treatment, biosimilar developers are facing yet another challenge: competing against reference products for a preferred place on formularies.

Study Finds Biosimilar Infliximab CT-P13 Effective, Safe in IBD Patients

August 15th 2017

By Jackie Syrop

Article

A recent Spanish study concludes that CT-P13, a biosimilar of reference infliximab that has been approved in Korea, the European Union, and the United States, is efficacious and well tolerated in patients with moderate to severe Crohn’s disease (CD) or ulcerative colitis (UC).

Some German Physicians and Patients Reluctant to Accept Infliximab Biosimilars

August 14th 2017

By Jackie Syrop

Article

In 2014, Germany had the highest use of biosimilars in Europe, with around 50% volume uptake. Yet data found that German patients have shown some reluctance to accept biosimilars.

Infographic: The Developing Ulcerative Colitis Market

August 13th 2017

By The Center for Biosimilars Staff

Article

Spherix Global Insights’ recently released survey of 103 US gastroenterologists yields 3 key takeaways concerning the future of the increasingly competitive ulcerative colitis market.

Drug Makers Vie for Insulin Market Share, Patients Wait for Relief

August 12th 2017

By Kelly Davio

Article

Price competition in the US insulin market is heating up; Novo Nordisk reported in its second-quarter earnings call that its 2018 US insulin prices could drop below 2017 levels.